Clinical trials: Stage II Skin Cancer
Metastatic Breast Cancer
PhII ICb With/Without Erbitux in MBC Pts
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
- Trial name
- CA225200 (NCT00248287)
- Testing
- Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux
- Where
- 59 sites in United States
- Volunteers
- 154 people
- Sponsor
- US Oncology Research
Breast Cancer
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Breast cancer is the most common malignancy in the U.S. Targeted therapies such as tamoxifen have been revolutionary in reducing tumor recurrences and mortality in early breast cancer.
- Trial name
- HELEX (NCT00999804)
- Testing
- Lapatinib, Letrozole, Trastuzumab
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Baylor Breast Care Center
Breast Cancer
Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer
Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer
- Trial name
- NCT04780347
- Testing
- Albumin-bound paclitaxel plus capecitabine, capecitabine
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Fudan University
Breast Cancer
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
- Trial name
- NCT04542135
- Testing
- Sulindac Pill
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Alison Stopeck
Metastatic Melanoma
Metronomic Therapy in Patients With Metastatic Melanoma
SUMMARY: Metronomic Therapy in Patients with Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine. Patients with measurable metastatic melanoma are eligible.
- Trial name
- NCT01542255
- Testing
- vinblastine, Cyclophosphamide, dacarbazine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors
This study gathers information to create a database to improve the ability to diagnose cancer, predict long term health of breast cancer patients, and help develop future treatment products.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04999826
- Testing
- Biospecimen Collection, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Carcinoma, Breast Lump
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
This randomized phase II trial studies how well carboplatin and paclitaxel with or without panitumumab work in treating patients with invasive triple negative breast cancer.
- Conditions
- Breast Carcinoma, Breast Lump, Edema, Erythema
- Trial name
- NCT02876107
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
RATIONALE: Pyridoxine (vitamin B6) and topical urea/lactic acid-based cream may prevent or lessen hand-foot syndrome caused by chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00296036
- Testing
- pyridoxine hydrochloride, urea/lactic acid-based topical cream
- Where
- 231 sites in United States
- Volunteers
- 137 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Breast Cancer
Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)
Lapatinib in combination with capecitabine has been approved for the treatment of women with HER-2-positive advanced breast cancer that have progressed after anthracycline-, taxane-, and trastuzumab-containing therapies.
- Trial name
- NCT01534455
- Testing
- Lapatinib + 1,23 mg Eribulin, Lapatinib + 1,76 mg Eribulin
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer, Estrogen Receptor Positive Tumor
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in…
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
- Trial name
- TOUCH (NCT03644186)
- Testing
- Paclitaxel, Trastuzumab, Pertuzumab
- Where
- 54 sites in Belgium, France and 2 more
- Volunteers
- 147 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Vaccine Therapy in Treating Patients With Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00004156
- Testing
- MUC1-KLH vaccine/QS21
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain
Pilot Study of Hydroxychloroquine for the Treatment of AIMSS
The purpose of this study is to evaluate the effectiveness of hydroxychloroquine sulfate (a type of drug commonly used to treat joint pain caused by inflammation, swelling) in reducing joint pain associated with Aromatase…
- Conditions
- Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
- Trial name
- AIMSS (NCT07825454)
- Testing
- Hydroxychloroquine Sulfate (HCQ)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Indiana University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
This phase II trial studies how well hypofractionated radiotherapy before (preoperative) or after (postoperative) breast surgery works in treating patients with different types of non-metastatic (has not spread from original…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma
- Trial name
- NCT06635980
- Testing
- Biopsy of Breast, Biospecimen Collection, Breast Surgery
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Mayo Clinic
Breast Cancer
Effect of Fluvastatin on Biomarkers in Women Who Are Undergoing Surgery for Ductal Carcinoma In Situ or Stage I Breast Cancer
RATIONALE: Collecting samples of blood and tissue from patients with cancer to study in the laboratory may help doctors learn how fluvastatin effects biomarkers related to breast cancer.
- Trial name
- NCT00416403
- Testing
- fluvastatin sodium, Breast Cancer Surgery Only - Arm III
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
This trial was designed to evaluate the maximum tolerated dose (MTD) and phase II recommended dose (RP2D) in subjects with TQB3912 tablets combined with fulvestrant injection and TQB3616 capsules for locally advanced or…
- Trial name
- NCT06851442
- Testing
- TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
- Where
- 17 sites in China
- Volunteers
- 8 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer
Forty years ago clinical studies conducted by Ewan Cameron and Linus Pauling suggested that intravenous (IV) and oral ascorbic acid (AA) may diminish symptoms and could improve survival in terminal cancer patients.
- Trial name
- NCT03175341
- Testing
- Ascorbic Acid
- Where
- Romania
- Volunteers
- 30 people
- Sponsor
- Academic Emergency County Hospital Sibiu
Breast Cancer
Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Aromatase inhibitors, such as letrozole, anastrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- MNEMOSYNE (NCT00893061)
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in France
- Volunteers
- 44 people
- Sponsor
- Centre Oscar Lambret
Breast Cancer
BMS-247550 in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating women who have stage IV or…
- Trial name
- NCT00020904
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
This is an open label, single centre, phase II study of neoadjuvant drug treatment with dabrafenib + trametinib in patients with resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 mutation positive…
- Trial name
- Neo Combi (NCT01972347)
- Testing
- Dabrafenib, Trametinib
- Where
- Australia
- Volunteers
- 35 people
- Sponsor
- Melanoma Institute Australia
Breast Cancer
De-Escalation of Axillary Management in Advanced Nodal Disease
This is a prospective, phase 2, single arm trial to evaluate whether Axillary Lymph Node Dissection (ALND) can be safely omitted for patients with cN2 and cN3 breast cancer who achieve a complete clinical response on exam with a…
- Trial name
- DEMAND (NCT07643584)
- Testing
- Axillary Surgery
- Volunteers
- 120 people
- Sponsor
- University of Kansas Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.